Skip to main content
BioCardia, Inc. logo

BioCardia, Inc. — Investor Relations & Filings

Ticker · BCDA ISIN · US09060U5074 LEI · 5493003EDBXRQRW22O75 US Manufacturing
Open in API
Filings indexed 1,022 across all filing types
Latest filing 2021-08-12 Earnings Release
Country US United States of America
Listing US BCDA

About BioCardia, Inc.

https://www.biocardia.com/

BioCardia, Inc. is a clinical-stage regenerative medicine company that develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. The company's lead program is the CardiAMP® cell therapy system, an autologous therapy that uses a patient's own bone marrow cells to potentially stimulate the body's natural healing response in the heart. This therapy is primarily being evaluated for the treatment of ischemic heart failure. In addition to its autologous platform, BioCardia is also developing CardiALLO™, an allogeneic cell therapy platform using cells from qualified donors. The company's approach integrates biotherapeutic candidates with proprietary delivery systems for targeted administration.

Recent filings

Filing Released Lang Actions
Earnings Release 2021
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 12, 2021, reporting the issuance of a press release announcing financial results for the quarter ended June 30, 2021. The text explicitly states that the press release is furnished as an exhibit and that the Form 8-K is a current report, not the financial report itself. The document length is 3369 characters, which is relatively short and consistent with an announcement rather than a full financial report. The document does not contain detailed financial statements or substantive financial data but rather announces the release of such information. Therefore, this filing is best classified as an Earnings Release (ER), which is the initial announcement of quarterly financial results.
2021-08-12 English
Interim / Quarterly Report 2021
Interim / Quarterly Report Q2 2021
2021-08-12 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce specific events or updates about the company. The content describes a patent grant event and includes a press release as an exhibit. The document is relatively short (3709 characters) and does not contain financial statements or detailed financial data. It is an announcement of an event rather than a financial report or detailed management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2021-07-15 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated June 23, 2021. It reports a press release about a Data Safety Monitoring Board review for a clinical trial, with no financial statements or detailed financial data included. The document is short (3914 characters) and primarily serves as a regulatory announcement of an event rather than a financial report or detailed management discussion. It does not contain quarterly or annual financial results, nor does it include management or board changes, capital updates, or legal proceedings. The content fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2021-06-23 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text includes standard SEC Form 8-K headers and sections, including Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. The content describes a press release about data presentation at a conference, attached as an exhibit. There are no financial statements or detailed financial data included. The document length is 3215 characters, which is relatively short and consistent with a current report rather than a full financial report. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous SEC filings like Form 8-K that do not fit other specific categories.
2021-06-22 English
Major Shareholding Notification 2021
Major Shareholding Notification
2021-06-21 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.